Treating metastatic prostate cancer in very elderly men: a review

A helpful review article on the treatment of metastatic and metastatic, castration-resistant prostate cancer (mCRPC) in very elderly men appears in last month’s issue of Clinical Interventions in Aging. … READ MORE …

Incidence, outcomes, ethnicity, and distant, de novo, metastatic prostate cancer

Diagnosis of men with distant, metastatic prostate cancer at first presentation (distant, “de novo”, metastatic prostate cancer) is a lot less common today than it was 30 or 40 years ago, but it does still happen on a regular basis. … READ MORE …

Results of Prostvac PROSPECT trial scheduled for later in 2017

According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017. … READ MORE …

No sign of evident clinical benefit in the Phase IV PLATO trial

According to a recent media release, there was no significant benefit for the investigational combination of enzalutamide (Xtandi) + abiraterone acetate (Zytiga) + prednisone in treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (cnmCRPC). … READ MORE …

Lu-177-PSMA-617: another update

Because there is great interest in systemic therapies for metastatic prostate cancer, we want to provide readers with the latest news about the 177Lu PSMA-617 trials in Germany. … READ MORE …

Data from the Phase III clinical trial of ipilimumab

Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.

Non-rising PSA but radiographic progression in men on treatment with enzalutamide

A recent presentation at the European Society of Medical Oncology (ESMO) annual meeting in Copenhagen, Denmark, has suggested that some men on treatment with enzalutamide (Xtandi) may have radiographic progression of their cancer even though there is no increase in their PSA levels. … READ MORE …